NCT03531840View on ClinicalTrials.gov

Olaparib in People With Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

December 4, 2019

Study Completion Date

October 21, 2020

Conditions
Mesothelioma
Interventions
DRUG

Olaparib

All subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity

DEVICE

ClinOmics

Non-significant risk (NSR) device

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03531840 - Olaparib in People With Malignant Mesothelioma | Biotech Hunter | Biotech Hunter